AG019
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AG019, covering 2023-02-01 to 2023-02-01. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) [Phase 1, Phase 2]